What is the recommended adult dose of injectable Nospa (drotaverine) for acute abdominal pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Injectable Nospa (Drotaverine) Dosing for Acute Abdominal Pain in Adults

The recommended adult dose of injectable Nospa (drotaverine hydrochloride) for acute abdominal pain is 40-80 mg administered intramuscularly or intravenously, which may be repeated if necessary, with a maximum daily dose not exceeding 240 mg.

Evidence-Based Dosing Protocol

The dosing for injectable drotaverine in acute abdominal pain is derived from clinical research rather than the provided FDA label (which appears to be for a different nasal formulation 1). Based on high-quality clinical trials:

Standard Dosing Regimen

  • Initial dose: 40-80 mg IV or IM
  • Route: Intravenous or intramuscular administration
  • Repeat dosing: May repeat once after 30-40 minutes if pain relief is inadequate 2
  • Maximum daily dose: 240 mg total

Clinical Context and Efficacy

For renal/ureteric colic: A multicenter, randomized, double-blind trial demonstrated that 80 mg IV drotaverine (with option to repeat once) provided effective pain relief in 79% of patients within 40 minutes, compared to 46% with placebo (P < 0.001) 2. A comparative study showed 80 mg IM drotaverine achieved 52.4% pain reduction at 30 minutes and 61.3% at 60 minutes, with efficacy non-inferior to diclofenac 75 mg 3.

For acute infectious gastroenteritis with abdominal pain: Fixed-dose combination of drotaverine 80 mg with paracetamol 500 mg given orally three times daily showed superior pain relief compared to paracetamol alone, with onset of pain relief within 60 minutes 4.

Practical Administration Guidelines

Timing and Monitoring

  • Assess pain intensity using Visual Analogue Scale (VAS) before administration
  • Re-evaluate at 30-40 minutes post-injection
  • If pain reduction is <50%, consider repeat dose (second 80 mg injection)
  • Monitor for 2 hours after last dose to ensure sustained relief

Safety Profile

The most common side effects are minor and transient 2:

  • Temporary decrease in blood pressure (monitor in hemodynamically unstable patients)
  • Vertigo
  • Nausea or vomiting
  • No serious adverse effects reported in clinical trials

When to Use Drotaverine

Drotaverine is particularly effective for:

  • Smooth muscle spasm-related pain: Renal colic, biliary colic, intestinal colic
  • Acute gastroenteritis with cramping pain 4
  • Irritable bowel syndrome exacerbations 5

Contraindications and Cautions

  • Avoid in severe hepatic or renal impairment
  • Use caution in patients with cardiovascular instability
  • Not recommended as monotherapy for surgical emergencies requiring intervention

Clinical Decision Algorithm

  1. Confirm diagnosis: Ensure abdominal pain is from smooth muscle spasm (colicky, cramping quality) rather than peritonitis or surgical emergency 6

  2. Initial injection: Administer 40-80 mg IV/IM (80 mg preferred for moderate-severe pain)

  3. Assess at 30-40 minutes:

    • If ≥50% pain reduction → observe for recurrence
    • If <50% pain reduction → administer second 80 mg dose
  4. Consider rescue analgesia: If inadequate relief after two doses, add tramadol 100 mg IM or alternative analgesic 3

  5. Do not exceed: 240 mg total daily dose

Important caveat: While drotaverine is highly effective for spasmodic abdominal pain, it does not address underlying pathology. Patients with acute abdominal pain require appropriate diagnostic workup (imaging, laboratory studies) to exclude surgical emergencies such as appendicitis, bowel obstruction, or perforation 6. Drotaverine provides symptomatic relief while diagnostic evaluation proceeds, but should never delay necessary surgical intervention.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.